- Home
- WFC vs ABBV Comparison
WFC vs ABBV Comparison
Compare WFC & ABBV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WFC | ABBV |
|---|---|---|
| Founded | 1852 | 2012 |
| Country | United States | United States |
| Employees | 197466 | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 261.7B | 451.5B |
| IPO Year | 2020 | 2012 |
Fundamental Metrics
Financial Performance| Metric | WFC | ABBV |
|---|---|---|
| Price | $83.62 | $265.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 18 |
| Target Price | $96.59 | ★ $253.71 |
| AVG Volume (30 Days) | ★ 9.1M | 2.5M |
| Earning Date | 04-14-2026 | 04-29-2026 |
| Dividend Yield | 2.21% | ★ 3.39% |
| EPS Growth | ★ 16.57 | N/A |
| EPS | ★ 3.60 | 2.42 |
| Revenue | ★ $85,063,000,000.00 | $61,160,000,000.00 |
| Revenue This Year | $11.08 | $11.87 |
| Revenue Next Year | $4.76 | $8.12 |
| P/E Ratio | ★ $24.04 | $109.31 |
| Revenue Growth | N/A | ★ 8.57 |
| 52 Week Low | $72.78 | $190.75 |
| 52 Week High | $97.76 | $267.47 |
Technical Indicators
Market Signals| Indicator | WFC | ABBV |
|---|---|---|
| Relative Strength Index (RSI) | 45.62 | 58.10 |
| Support Level | $83.38 | $243.68 |
| Resistance Level | $86.89 | $264.26 |
| Average True Range (ATR) | 1.97 | 4.79 |
| MACD | -0.31 | 0.46 |
| Stochastic Oscillator | 9.54 | 85.17 |
Price Performance
Historical ComparisonAbout WFC Wells Fargo & Company
Wells Fargo is a premier, North American-focused banking titan that commands a $2.2 trillion balance sheet and the third-highest deposit market share in the United States. The bank uses a dense, expansive network of 4,093 branches to champion retail consumers and the middle market, where the firm has built a particularly strong reputation. Following the removal of its federal asset cap in 2025, the firm is set to deploy its legacy excess liquidity to expand each of its four segments: consumer & business lending, commercial banking, corporate & investment banking, and wealth & investment management.
About ABBV AbbVie Inc.
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.